Arcturus' COVID-19 mRNA Vaccine Candidate To Target Variants, Trial To Start In Vietnam

• The Vietnam Ministry of Health has signed off Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) Clinical Trial Application (CTA) to advance ARCT-154 COVID19 vaccine candidate targeting variants of concern.

• The ARCT-154 Phase 1/2/3 clinical study is a randomized, observer-blind, placebo-controlled design and is sponsored and entirely funded by Arcturus' manufacturing partner Vinbiocare, a subsidiary of Vingroup.

• The study will assess the safety, immunogenicity, and efficacy of the SARS-CoV-2 self-amplifying mRNA vaccine in adults 18 years or older and enroll up to 21,000 participants across the 3 phases, with 20,000 in Phase 3.

• Primary endpoints include safety and efficacy with immunogenicity being evaluated in a subgroup.

• If the study proves successful at interim evaluations, Emergency Use Approval (EUA) by the Vietnam Ministry of Health is anticipated in December 2021.

• Vinbiocare and Arcturus also announced to establish a manufacturing plant for the COVID-19 vaccines.

• Price Action: ARCT shares are up 9.10% at $34.16 during the market session on the last check Monday.

• Related content: Benzinga's Full FDA Calendar.

See more from Benzinga

• Click here for options trades from Benzinga

• Arcturus Therapeutics Stock Jumps On Establishment Of COVID-19 Vaccine Plant In Vietnam

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.